Talks and discussions covering peptide therapeutic development are key parts to our symposium. In addition, we hold special panels covering topics that include regulatory affairs, quality assurance, and venture capitial investments. The panels feature discussions from FDA, CFDA and USP experts on evolving regulatory environments in the pharmaceutical industry.
This Year’s Symposium Speakers
A partial list of speakers for CPC Symposium 2019
| Paul Alewood, Professor Institute for Molecular Bioscience, The University of Queensland, Australia |
| Dana Ault-Riche, Co-Founder and CEO Reflexion Pharmaceuticals |
| Yuan Cheng, Principal Scientist Amgen |
| David Craik , Professor Institute for Molecular Bioscience, The University of Queensland, Australia |
| John Dodd, Vice President Palatin Technologies |
| Chris Holmes, Vice president Apellis Pharmaceuticals |
| Harri Jarvelainen, COO DrudCendR Inc. |
| Claudia Jochheim, Sr. Vice President Blaze Bioscience |
| Sunghoon Kim, Distinguished University Professor and Director Medicinal Bioconvergence Research Center, College of Pharmacy, Seoul National University |
| Glenn King, Professor Institute for Molecular Bioscience, The University of Queensland, Australia |
| Henrik Ramirez-Andersen, Scientific Director Novo Nordisk |
| Chris Rhodes, President of Boulder Peptide Symposium; CEO, Drug Delivery Experts |
| Michael Verlander, President Proactive Quality Compliance, Inc |
| Hanmei Xu, Professor China Pharmaceutical University |